Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Andrea CercekGustavo Dos Santos FernandesCampbell S RoxburghKaruna GaneshShu NgFrancisco Sanchez-VegaRona YaegerNeil H SegalDiane L Reidy-LagunesAnna M VargheseArnold MarkowitzChao WuBryan C SzeglinCharles-Etienne Gabriel SauvéErin Salo-MullenChristina TranZalak PatelAsha KrishnanKaitlyn TkachukGarrett M NashJose GuillemPhilip B PatyJinru ShiaNikolaus SchultzJulio Garcia-AguilarLuis A DiazKaryn GoodmanLeonard B SaltzMartin R WeiserJ Joshua SmithZsofia K StadlerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Over one-fourth of dMMR rectal tumors treated with neoadjuvant chemotherapy exhibited disease progression. Conversely, dMMR rectal tumors were sensitive to chemoradiation. MMR status should be performed upfront in all locally advanced rectal tumors with careful monitoring for response on neoadjuvant chemotherapy and genetic testing for Lynch syndrome in patients with dMMR rectal cancer.